---
company: uniQure N.V.
ticker: QURE
form: 8-K
filed: 2026-11-04
accepted: 2026-11-04T12:10:24+00:00
accession: 0001104659-26-122362
source: https://www.sec.gov/Archives/edgar/data/1590560/000110465926122362/
quarterly_report: https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/
---

# uniQure (QURE) Q3 2026 earnings

## Header

- Company: uniQure N.V.
- Reported: 2026-11-04 07:10 BMO ET
- Source: 8-K only — accession 0001104659-26-122362, Item 2.02 + Exhibit 99.1
- Verdict: Net loss narrowed to $61.2 million as operating expenses rose but non-operating items improved.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---:|---:|---|
| Revenue | $5.2M | +40.5% | -10.5% | Ex. 99.1, income statement |
| EPS (GAAP) | $-0.88 | +36.2% | -32.7% | Ex. 99.1, income statement |

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: not stated in the 8-K
- Operating expenses: $59.7M (+10.1% YoY)
- One-offs in the quarter: Pre-funded warrant fair value loss $16.0M; Foreign currency loss $1.7M; Tax rate 7.2% (vs 12.0% YoY)
- Effective tax rate: 7.2% (vs 12.0% YoY)
- Non-GAAP bridge: No reconciliation provided.

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---:|
| Cash, cash equivalents and investment securities | $768.4M | $810.3M | $622.5M | -5.2% QoQ, +23.4% YoY |
| Weighted average shares | 69.9M | 66.2M | 54.8M | +5.6% QoQ, +27.7% YoY |

## Guidance

not stated in the 8-K

## What drove it

- Revenue story: License revenue increased to $5.2 million (+40.5% YoY) from $3.7 million, but declined 10.5% sequentially.
- EPS story: Loss per share narrowed due to lower net loss and a higher share count.
- One-off check: Pre-funded warrant fair value loss $16.0M; foreign currency loss $1.7M.

## The good

- Cash position of $768.4M expected to fund operations into 2030
- Net loss narrowed to $61.2 million from $80.5 million YoY
- Non-operating items improved to a $7.6M expense from a $20.9M expense YoY

## The bad

- SG&A expenses increased 22.9% YoY to $23.9 million
- R&D expenses increased 3.2% YoY to $35.5 million
- Revenue declined 10.5% QoQ to $5.2 million

## The ugly

- none

## Open questions

- What is the specific impact of the $16.0M pre-funded warrant fair value loss on the balance sheet?
- How will the $16.0M warrant loss and foreign currency loss affect future non-operating items?
- What are the specific drivers for the 37.4% QoQ increase in SG&A expenses?

## Full release

### uniQure (QURE) earnings release, November 4, 2026

uniQure N.V. (QURE) · Form 8-K, Item 2.02 · Filed 2026-11-04 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122362/)

uniQure

Announces Third Quarter 2026 Financial Results and

Provides

Company Update

~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~

~ Aligned with FDA on key elements of confirmatory study design; U.S. patient screening expected to begin by end of 2026 ~

~ Cash, cash equivalents and investment securities of approximately $768.4 million as of September 30, 2026 expected to fund operations into 2030 ~

~ uniQure to host earnings call at 8:30 a.m. ET

~

Lexington, MA and Amsterdam, the Netherlands,

November 4, 2026 — uniQure

N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2026 and highlighted recent progress across its business.

“Over the last few months, we have made significant progress in our mission to potentially deliver the first disease-modifying therapy to the patients and families living with Huntington’s disease,” said

Matthew Kapusta, chief executive officer at uniQure. “We strongly believe AMT-130 has the potential to deliver meaningful benefit to HD patients. With our BLA under Priority Review and preparations for the confirmatory study underway, we are committed to bringing this therapy to patients and families who continue to live with this devastating disease.”

"As we continue to build our commercial capabilities and prepare for a potential launch, we are energized by what lies ahead, and our financial strength provides us the runway to deliver on our plans,” Mr. Kapusta continued. “We are grateful to the patients, families and investigators who have made this progress possible, and are honored to continue to work alongside this community."

Recent Company Developments and Updates

Advancing ifezuntirgene inilparvovec towards potential accelerated approval for the treatment of Huntington’s disease

Continued clinical progress in pipeline programs

AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE)

AMT-191 for the treatment of Fabry disease

Focused execution and strong financial position

Financial Highlights

Cash Position:

As of September 30, 2026, the Company held $768.4 million in cash, cash equivalents and investment securities, compared to $622.5 million as of December 31, 2025. The Company expects that these resources will be sufficient to fund projected operating expenses into 2030.

Revenues:

Revenue for the three months ended September 30, 2026 was $5.2 million, compared to $3.7 million in the same period in 2025. The increase of $1.5 million is due to an increase in license revenue, compared to the prior period.

R&D Expenses:

Research and development expenses were $35.5 million for the three months ended September 30, 2026, compared to $34.4 million in the same period in 2025. The $1.1 million increase primarily resulted from a $3.6 million increase in employee and contractor-related expenses including share-based compensation partially offset by a $2.3 million decrease in direct research and development expenses. The decrease in direct research and development expenses resulted from a $4.1 million reduction in process validation expenses related to ifezuntirgene inilparvovec, a $1.5 million increase in expenses related to AMT-260 and a $1.7 million increase in expenses related to preclinical activities and technology innovation projects.

SG&A Expenses:

Selling, general and administrative expenses were $23.9 million for the three months ended September 30, 2026, compared to $19.4 million during the same period in 2025. The $4.5 million increase was primarily related to a $3.0 million increase in employee and contractor-related expenses, including share-based compensation, mainly as a result of the recruitment efforts over the last 12 to 15 months, a $0.7 million increase in professional fees and a $0.7 million increase in information technology costs to support the potential commercial launches of ifezuntirgene inilparvovec.

Non-Operating

Items, net:

Other non-operating items, net was an expense of $7.6 million for the three months ended September 30, 2026, compared to an expense of $20.9 million during the same period in 2025. The $13.3 million decrease in net non-operating expense was primarily due to $6.3 million reduction of expenses related to pre-funded warrants as well as $6.8 million improvement of net interest income.

Net loss:

The net loss for the three months ending September 30, 2026, was $61.2 million, or $0.88 basic and diluted loss per ordinary share, compared to $80.5 million net loss for the comparative period in 2025, or $1.38 basic and diluted loss per ordinary share.

Upcoming investor events:

Investor Conference Call and Webcast Information uniQure management will host an investor conference call and webcast today, Wednesday, November 4th at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 5075555. If you are joining the conference call, please join 15 minutes before the start time.

About uniQure uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a... (truncated)ers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com uniQure Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," “establish,” "estimate," "expect,"

"goal," "intend," "look forward to", "may," "plan," "potential," "predict,"

"project," “seek,” "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Examples of these forward-looking statements include, but are not limited to, statements concerning: the Company’s cash runway and its ability to fund its operations into 2030; its belief related to the potential for ifezuntirgene inilparvovec, if approved, to meaningfully reduce disease progression based on the Company’s evaluation and view of certain measurements of disease progression the Company’s ability and plans to strategically advance its programs, including the potential commercialization of ifezuntirgene inilparvovec; the Company’s future interactions with regulatory authorities and regulatory updates related to ifezuntirgene inilparvovec; the Company’s plans and ability to conduct a confirmatory study for ifezuntirgene inilparvovec , including the design, timing, endpoints and control arm of such study; ; and the Company’s plans to attend upcoming investor events. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: risks associated with the clinical results and the development and timing of the Company’s programs, including the risk that clinical results will be unable to demonstrate data sufficient to support further clinical development or regulatory approval in any country where approval is pursued; expectations regarding the adequacy of clinical data to support the marketing application and approval of ifezuntirgene inilparvovec; expectations regarding timing of receiving potential approval of ifezuntirgene inilparvovec; the risk that the FDA ultimately concludes that the Phase I/II trial data for ifezuntirgene inilparvovec are not sufficient to support approval of ifezuntirgene inilparvovec; the Company’s interactions with regulatory authorities, including the FDA and MHRA, which may affect the initiation, timing and progress of clinical trials and pathways and timing for regulatory approval for the Company’s other clinical candidates; the Company’s ability to conduct and fund any required confirmatory study for ifezuntirgene inilparvovec; the Company’s ability to successfully complete any required confirmatory study for ifezuntirgene inilparvovec ; the risk that accelerated approval, if granted, may be subject to post-approval requirements that are difficult or costly to satisfy; the Company’s ability to continue to build and maintain the infrastructure and personnel needed to achieve its goals; the Company’s effectiveness in managing current and future clinical trials and regulatory processes; the continued development and acceptance of gene therapies; the Company’s ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials; the Company’s ability to obtain, maintain and protect intellectual property; and the Company’s ability to fund its operations. These risks and uncertainties are more fully described under the heading "Risk Factors" in the Company’s periodic filings with the U.S.

Securities & Exchange Commission (“SEC”), including the Company’s Annual Reports on Form 10-K and Quarterly

Reports on Form 10-Q, and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and, except as required by law, the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future. uniQure Contacts:

#### Financial statements

##### Income Statement (Three months ended September 30, — UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, U.S dollars, except share and per share amounts))

| | Three months ended September 30, – 2026 | Three months ended September 30, – 2025 |
|---|---:|---:|
| Total revenues | 5,196 | 3,701 |
| **Operating expenses:** | | |
| Cost of license revenues | -236 | -398 |
| Research and development expenses | -35,517 | -34,366 |
| Selling, general and administrative expenses | -23,918 | -19,438 |
| Total operating expenses | -59,671 | -54,202 |
| Other income | 1,690 | 1,510 |
| Other expense | -195 | -2,044 |
| Loss from operations | -52,980 | -51,035 |
| Non-operating items, net | -7,561 | -20,868 |
| Loss before income tax expense | -60,541 | -71,903 |
| Income tax expense | -676 | -8,626 |
| Net loss | -61,217 | -80,529 |
| Basic and diluted net loss per ordinary share | -0.88 | -1.38 |
| Weighted average shares used in computing basic and diluted net loss per ordinary share | 69,900,863 | 58,516,415 |

##### Balance Sheet (September 30, — UNAUDITED CONSOLIDATED BALANCE SHEETS (in thousands))

| | September 30, – 2026 | December 31, – 2025 |
|---|---:|---:|
| **Current assets** | | |
| Cash and cash equivalents | 98,442 | 80,240 |
| Current investment securities | 570,021 | 542,301 |
| Accounts receivable | 4,804 | 5,863 |
| Prepaid expenses | 9,601 | 20,506 |
| Other current assets and receivables | 9,677 | 7,076 |
| Total current assets | 692,545 | 655,986 |
| **Non-current assets** | | |
| Property, plant and equipment, net | 9,923 | 13,800 |
| Other investments | 31,539 | 30,237 |
| Non-current investment securities | 99,967 |  |
| Operating lease right-of-use assets | 10,980 | 12,525 |
| Intangible assets, net | 61,855 | 72,790 |
| Goodwill | 24,503 | 25,355 |
| Deferred tax assets, net | 5,709 | 8,654 |
| Other non-current assets | 3,530 | 5,561 |
| Total non-current assets | 248,006 | 168,922 |
| Total assets | 940,551 | 824,908 |
| **Current liabilities** | | |
| Accounts payable | 6,173 | 5,170 |
| Accrued expenses and other current liabilities | 50,979 | 41,292 |
| Liability related to pre-funded warrants |  | 12,595 |
| Current portion of operating lease liabilities | 2,990 | 3,862 |
| Total current liabilities | 60,142 | 62,919 |
| **Non-current liabilities** | | |
| Long-term debt | 50,345 | 49,699 |
| Liability from royalty financing agreement | 497,271 | 473,199 |
| Operating lease liabilities, net of current portion | 9,032 | 9,832 |
| Contingent consideration | 18,742 | 18,736 |
| Deferred tax liability, net | 7,699 | 7,967 |
| Other non-current liabilities, net of current portion | 2,667 | 3,655 |
| Total non-current liabilities | 585,756 | 563,088 |
| Total liabilities | 645,898 | 626,007 |
| **Shareholders' equity** | | |
| Total shareholders' equity | 294,653 | 198,901 |
| Total liabilities and shareholders' equity | 940,551 | 824,908 |

##### Cash Flow (From the 10-Q · Nine months ended September 30, — UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands))

| | Nine months ended September 30, – 2026 | Nine months ended September 30, – 2025 |
|---|---:|---:|
| **Cash flows used in operating activities** | | |
| Net loss | -195,811 | -161,885 |
| **Adjustments to reconcile net loss to net cash used in operating activities:** | | |
| Depreciation and amortization | 13,313 | 11,789 |
| Amortization of discount on investment securities | -13,599 | -6,091 |
| Share-based compensation expense | 15,552 | 13,016 |
| Royalty financing agreement interest expense, net of interest paid | 23,353 | 29,209 |
| Deferred tax expense | 2,945 | 1,979 |
| Changes in fair value of contingent consideration | 616 | 5,293 |
